Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab Plus Bevacizumab in Resected Hepatocellular Carcinoma	Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm	Recruiting	Phase 2	2026-06-29		NCT05516628

14 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Cancer Science Institute of Singapore	3
Changi General Hospital	29
Duke-NUS Graduate Medical School	36
Genome Institute of Singapore	7
Institute of Molecular and Cell Biology of Singapore	1
Nanyang Technological University	30
National Cancer Centre, Singapore	44
National University Hospital, Singapore	120
NMRC OF-LCG (OFLCG21Jun-0016)	1
Sengkang General Hospital	17
Singapore Clinical Research Institute	5
Singapore General Hospital	80
Singapore Phenome Centre	3
Tan Tock Seng Hospital	33

6 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Changi General Hospital	Singapore	Singapore	19
National Cancer Centre Singapore	Singapore	Singapore	15
National University Hospital Singapore	Singapore	Singapore	14
Sengkang General Hospital	Singapore	Singapore	14
Singapore General Hospital	Singapore	Singapore	7
Tan Tock Seng Hospital	Singapore	Singapore	47